NEW YORK — Digital pathology company PathAI said on Monday that it has secured an additional $15 million in Series B financing, bringing the total money raised in the round to $75 million.
The new investment, which came from Merck Global Health Innovation Fund and Bristol-Myers Squibb, adds to the $60 million in Series B money the Boston-based firm raised earlier this year. PathAI, which also received an unspecified investment from Laboratory Corporation of America in July, said it has raised over $90 million since it was founded in 2016
PathAI has developed a pathology research platform that uses artificial intelligence to assist pathologists in making accurate diagnoses from patient tissue samples. It has collaborations with Royal Philips, Bristol-Myers Squibb, and LabCorp.